General Manager Ketil Widerberg (to the left) and Chairman of the Board Øyvind Kongstun Arnesen (to the right) welcomed the new Board Member Ingvild Stenstadvold Ross after the General Assembly 2023. Leif Rune Skymoen was not on-site when the picture was taken. Photo: Sofia Linden / Oslo Cancer Cluster.

Oslo Cancer Cluster strengthens the board

/in , /by

Patient and industry perspectives are key as new board members join Oslo Cancer Cluster.

Ingrid Stenstadvold Ross, CEO of the Norweigan Cancer Society, and Leif Rune Skymoen, general manager of the Association of the Pharmaceutical Industry in Norway (Legemiddelindustrien – LMI) were voted into the board of Oslo Cancer Cluster at the General Assembly in May 2023.

Both newcomers bring a strong focus on the development of Norwegian health industry and collaboration between public and private partners – to improve patient’s lives.

Helping cancer companies

“I am grateful for this trust and look forward to starting the work in the board of Oslo Cancer Cluster. The most important issue for me is to contribute to the development of Norwegian health industry that creates new solutions and treatments for future patients.

“We need to work so the incredibly important cancer companies in the cluster get the best circumstances going forward. This means a special focus on the development of the Radiumhospital Campus and to secure that Norwegian companies in cancer get maximal opportunities through the EU Mission on Cancer, as well as, to use my experience in communication and political advocacy to influence the framework for the Norwegian health industry,” commented Ingrid Stenstadvold Ross.

Stenstadvold Ross has worked in the field of cancer for almost 10 years and has almost 20 years of experience in political advocacy, organisational development, and leadership within different NGO’s. Ross is also deputy chairman of the board of Abelia, and chair of the board of the European Fair Pricing Network.

Putting Norway on the map

“Oslo Cancer Cluster has through many years been an important driver for collaboration between different actors in the cancer field and an energic ambassador for Norway internationally. I am thankful for this opportunity to contribute to that research and development in the Norwegian cancer milieu benefits even more patients. And to build a new industry in a field where Norway has an extraordinary opportunity to succeed,” Skymoen commented.

Leif Rune Skymoen, general manager of LMI.

Skymoen has held several leadership roles in the Norwegian health industry, including Country Director for Eli Lilly Norway, CEO of Nansen Neuroscience, and co-founder and CEO of Curida.

 

The post Oslo Cancer Cluster strengthens the board first appeared on Oslo Cancer Cluster.